首页 > 最新文献

Multiple Sclerosis Journal最新文献

英文 中文
Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review. 多发性硬化症患者与奥克立珠单抗相关的隐源性组织化肺炎:两份病例报告和全面的文献综述。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-21 DOI: 10.1177/13524585241295677
Alessandro Gans, Elena Pinuccia Verrengia, Elisabetta Ricchiuti, Serena Leva, Simona Brajkovic, Daniele Colombo, Antonino Mazzone, Alessandro Prelle

Background: Cryptogenic organizing pneumonia (COP) is an interstitial lung disease, with causes including anti-CD20 antibodies. Ocrelizumab is a humanized monoclonal antibody against CD20 approved for use in relapsing-remitting or primary progressive multiple sclerosis (MS), with no conclusive data regarding pulmonary toxicity.

Cases: We describe two cases of COP associated with ocrelizumab use in multiple sclerosis patients.

Conclusions: We suggest considering COP whenever respiratory symptoms arise in MS patients receiving ocrelizumab therapy. COP diagnosis requires clinical and radiological exclusion of alternative diagnoses such as opportunistic infections, autoimmunity, drugs, and neoplasms. Appropriate steroid therapy has an excellent clinical response rate.

背景:隐源性组织化肺炎(COP)是一种间质性肺病,病因包括抗CD20抗体。奥克立珠单抗是一种抗 CD20 的人源化单克隆抗体,已被批准用于治疗复发性缓解型或原发性进展型多发性硬化症(MS),目前尚无有关肺毒性的确凿数据:我们描述了两例与多发性硬化症患者使用奥克立珠单抗相关的 COP 病例:我们建议接受奥克立珠单抗治疗的多发性硬化症患者在出现呼吸道症状时考虑 COP。COP的诊断需要通过临床和放射学排除其他诊断,如机会性感染、自身免疫、药物和肿瘤。适当的类固醇治疗具有极佳的临床反应率。
{"title":"Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review.","authors":"Alessandro Gans, Elena Pinuccia Verrengia, Elisabetta Ricchiuti, Serena Leva, Simona Brajkovic, Daniele Colombo, Antonino Mazzone, Alessandro Prelle","doi":"10.1177/13524585241295677","DOIUrl":"https://doi.org/10.1177/13524585241295677","url":null,"abstract":"<p><strong>Background: </strong>Cryptogenic organizing pneumonia (COP) is an interstitial lung disease, with causes including anti-CD20 antibodies. Ocrelizumab is a humanized monoclonal antibody against CD20 approved for use in relapsing-remitting or primary progressive multiple sclerosis (MS), with no conclusive data regarding pulmonary toxicity.</p><p><strong>Cases: </strong>We describe two cases of COP associated with ocrelizumab use in multiple sclerosis patients.</p><p><strong>Conclusions: </strong>We suggest considering COP whenever respiratory symptoms arise in MS patients receiving ocrelizumab therapy. COP diagnosis requires clinical and radiological exclusion of alternative diagnoses such as opportunistic infections, autoimmunity, drugs, and neoplasms. Appropriate steroid therapy has an excellent clinical response rate.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585241295677"},"PeriodicalIF":4.8,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
To halt disease progression rehabilitation in MS should start early: No. 多发性硬化症的康复治疗应及早开始,以阻止疾病进展:不
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 DOI: 10.1177/13524585241289277
Declan T Chard
{"title":"To halt disease progression rehabilitation in MS should start early: No.","authors":"Declan T Chard","doi":"10.1177/13524585241289277","DOIUrl":"10.1177/13524585241289277","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":"30 13","pages":"1594-1595"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Employment, work hours, and wages in adults with myelin oligodendrocyte glycoprotein antibody disease: An international cohort study. 患有髓鞘少突胶质细胞糖蛋白抗体病的成年人的就业、工作时间和工资:一项国际队列研究。
IF 5.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 Epub Date: 2024-10-11 DOI: 10.1177/13524585241286671
Andrew Siyoon Ham, Isabella Gomez Hjerthen, Akshatha Sudhir, Lekha Pandit, Y Muralidhar Reddy, Jagarlapudi Muralikrishna Murthy, De-Cai Tian, Hongfei Gu, Wen Gao, Simon A Broadley, Unnah Leitner, Amelia Yun Yi Aw, Kevin Tan, Tianrong Yeo, Saúl Reyes, Jaime Toro, Jairo Gaitán, Deyanira Altagracia Ramírez, Raúl Comme-Debroth, Josmarlin Patricia Medina Báez, Bade Gulec, Ugur Uygunoglu, Melih Tutuncu, Aksel Siva, Raffaele Iorio, Eleonora Sabatelli, Saif Huda, Patricia Kelly, Juan Ignacio Rojas, Edgardo Cristiano, Liliana Patrucco, Enedina Maria Lobato de Oliveira, Raquel Paiva Portugal, Paloma Peter Travassos Zaidan, Shanthi Viswanathan, Karina Koh, Su-Yin Lim, Farrah J Mateen

Objectives: The objectives were to understand the employment impacts of myelin oligodendrocyte glycoprotein-associated antibody disease (MOGAD) on adults in an international cohort by determining lost employment, work hours, and wages.

Background: Clinically, MOGAD can be associated with significant disability; however, its socioeconomic consequences for adults are barely reported.

Methods: Participants of potential working age (18-70 years old) with neurologist-diagnosed MOGAD were recruited from clinical sites in 13 countries, April 2022 to August 2023. Each participant completed a one-time survey. Regression models assessed associations with post-MOGAD (1) unemployment and (2) work hours.

Results: A total of 117 participants (66.7% female), mean age 39.7 years, median disease duration 3 years (25th, 75th percentile: 1, 7) were analyzed. Employment post-MOGAD reduced from 74 (63.2%) to 57 (48.7%) participants. Participants employed pre-diagnosis reduced their work hours, on average, from 31.6 hours/week to 19.5 hours/week post-diagnosis. Residence in a high-income country was statistically significantly associated with post-diagnosis employment and higher weekly work hours. Depressed mood was associated with unemployment. MOGAD-related pain and history of myelitis were independently associated with lost work hours.

Conclusion: MOGAD can have significant impacts on adult employment, particularly in non-high-income countries. Depressed mood and pain are potentially modifiable factors related to socioeconomic status in MOGAD.

目标:目的:通过确定损失的就业、工作时间和工资,了解髓鞘少突胶质细胞糖蛋白相关抗体病(MOGAD)对国际队列中成年人就业的影响:背景:临床上,少突胶质细胞糖蛋白相关抗体病会导致严重的残疾;然而,该病对成年人造成的社会经济后果却鲜有报道:方法:2022 年 4 月至 2023 年 8 月,我们从 13 个国家的临床研究机构招募了潜在工作年龄(18-70 岁)、经神经科医生诊断患有 MOGAD 的参与者。每位参与者都完成了一次性调查。回归模型评估了与 MOGAD 后(1)失业率和(2)工作时间的关联:共分析了 117 名参与者(66.7% 为女性),平均年龄 39.7 岁,中位病程 3 年(第 25、75 百分位数:1、7)。MOGAD后就业的参与者从74人(63.2%)减少到57人(48.7%)。诊断前就业的参与者平均每周工作时间从 31.6 小时减少到诊断后的 19.5 小时。在统计学上,居住在高收入国家与诊断后的就业和每周较高的工作时间有明显的相关性。抑郁情绪与失业有关。与 MOGAD 相关的疼痛和脊髓炎病史与工时损失独立相关:结论:骨髓增生异常放电对成人就业有重大影响,尤其是在非高收入国家。抑郁情绪和疼痛是与多发性骨髓增生异常综合症患者社会经济地位相关的潜在可调节因素。
{"title":"Employment, work hours, and wages in adults with myelin oligodendrocyte glycoprotein antibody disease: An international cohort study.","authors":"Andrew Siyoon Ham, Isabella Gomez Hjerthen, Akshatha Sudhir, Lekha Pandit, Y Muralidhar Reddy, Jagarlapudi Muralikrishna Murthy, De-Cai Tian, Hongfei Gu, Wen Gao, Simon A Broadley, Unnah Leitner, Amelia Yun Yi Aw, Kevin Tan, Tianrong Yeo, Saúl Reyes, Jaime Toro, Jairo Gaitán, Deyanira Altagracia Ramírez, Raúl Comme-Debroth, Josmarlin Patricia Medina Báez, Bade Gulec, Ugur Uygunoglu, Melih Tutuncu, Aksel Siva, Raffaele Iorio, Eleonora Sabatelli, Saif Huda, Patricia Kelly, Juan Ignacio Rojas, Edgardo Cristiano, Liliana Patrucco, Enedina Maria Lobato de Oliveira, Raquel Paiva Portugal, Paloma Peter Travassos Zaidan, Shanthi Viswanathan, Karina Koh, Su-Yin Lim, Farrah J Mateen","doi":"10.1177/13524585241286671","DOIUrl":"10.1177/13524585241286671","url":null,"abstract":"<p><strong>Objectives: </strong>The objectives were to understand the employment impacts of myelin oligodendrocyte glycoprotein-associated antibody disease (MOGAD) on adults in an international cohort by determining lost employment, work hours, and wages.</p><p><strong>Background: </strong>Clinically, MOGAD can be associated with significant disability; however, its socioeconomic consequences for adults are barely reported.</p><p><strong>Methods: </strong>Participants of potential working age (18-70 years old) with neurologist-diagnosed MOGAD were recruited from clinical sites in 13 countries, April 2022 to August 2023. Each participant completed a one-time survey. Regression models assessed associations with post-MOGAD (1) unemployment and (2) work hours.</p><p><strong>Results: </strong>A total of 117 participants (66.7% female), mean age 39.7 years, median disease duration 3 years (25th, 75th percentile: 1, 7) were analyzed. Employment post-MOGAD reduced from 74 (63.2%) to 57 (48.7%) participants. Participants employed pre-diagnosis reduced their work hours, on average, from 31.6 hours/week to 19.5 hours/week post-diagnosis. Residence in a high-income country was statistically significantly associated with post-diagnosis employment and higher weekly work hours. Depressed mood was associated with unemployment. MOGAD-related pain and history of myelitis were independently associated with lost work hours.</p><p><strong>Conclusion: </strong>MOGAD can have significant impacts on adult employment, particularly in non-high-income countries. Depressed mood and pain are potentially modifiable factors related to socioeconomic status in MOGAD.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1674-1682"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding the spectrum of NMOSD: New cases of autoimmune epilepsy and meningoencephalitis. 扩大 NMOSD 的范围:自身免疫性癫痫和脑膜脑炎的新病例。
IF 5.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-30 DOI: 10.1177/13524585241261545
Edgar Carnero Contentti
{"title":"Expanding the spectrum of NMOSD: New cases of autoimmune epilepsy and meningoencephalitis.","authors":"Edgar Carnero Contentti","doi":"10.1177/13524585241261545","DOIUrl":"10.1177/13524585241261545","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1696-1697"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder. 抗 AQP4-Ab 相关神经脊髓炎视网膜谱系障碍中的复发性脑膜炎和边缘性脑炎。
IF 5.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-30 DOI: 10.1177/13524585241261549
Giovanni Novi, Elvira Sbragia, Luana Benedetti, Angelo Schenone, Antonio Uccelli, Roberta Magliozzi, Massimo Del Sette, Matilde Inglese, Alice Laroni

Objectives: neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease mainly affecting optic nerves and the spinal cord. Due to the potentially irreversible tissue damage, prevention of relapses is of utmost importance.

Methods: We describe the atypical clinical course and pathology results of a patient with anti-aquaporin-4 antibody (anti-AQP4-Ab)-associated NMOSD who developed aseptic meningitis followed by limbic-encephalitis-like presentation with extensive brain lesions upon treatment with rituximab and tocilizumab.

Results: The patient developed subacute cognitive decline with magnetic resonance imaging (MRI) evidence of extensive brain white matter lesions. In the hypothesis of an opportunistic brain infection, she underwent brain biopsy of the temporal pole. Pathology results revealed typical NMOSD findings with complement activation, supporting the hypothesis of an atypical presentation of anti-AQP-Ab-associated NMOSD. Accordingly, treatment with the complement-targeting drug eculizumab was started, leading to a dramatic clinical and MRI improvement.

Discussion: aseptic meningitis and limbic encephalitis could represent a rare phenotype of anti-AQP4-Ab-associated NMOSD.

目的:神经脊髓炎视谱系障碍(NMOSD)是一种罕见的自身免疫性疾病,主要影响视神经和脊髓。由于可能造成不可逆的组织损伤,因此预防复发至关重要:我们描述了一名抗喹诺酮-4 抗体(anti-AQP4-Ab)相关 NMOSD 患者的非典型临床过程和病理结果,该患者在接受利妥昔单抗和托珠单抗治疗后,出现无菌性脑膜炎,继而出现边缘脑炎样表现,并伴有广泛的脑损伤:结果:患者出现亚急性认知功能下降,磁共振成像(MRI)显示脑白质广泛病变。在脑部机会性感染的假设下,她接受了颞极的脑活检。病理检查结果显示,她患有典型的补体激活型NMOSD,支持了抗AQP-Ab相关NMOSD非典型表现的假设。讨论:无菌性脑膜炎和肢端脑炎可能是抗AQP4-Ab相关性NMOSD的一种罕见表型。
{"title":"Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder.","authors":"Giovanni Novi, Elvira Sbragia, Luana Benedetti, Angelo Schenone, Antonio Uccelli, Roberta Magliozzi, Massimo Del Sette, Matilde Inglese, Alice Laroni","doi":"10.1177/13524585241261549","DOIUrl":"10.1177/13524585241261549","url":null,"abstract":"<p><strong>Objectives: </strong>neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease mainly affecting optic nerves and the spinal cord. Due to the potentially irreversible tissue damage, prevention of relapses is of utmost importance.</p><p><strong>Methods: </strong>We describe the atypical clinical course and pathology results of a patient with anti-aquaporin-4 antibody (anti-AQP4-Ab)-associated NMOSD who developed aseptic meningitis followed by limbic-encephalitis-like presentation with extensive brain lesions upon treatment with rituximab and tocilizumab.</p><p><strong>Results: </strong>The patient developed subacute cognitive decline with magnetic resonance imaging (MRI) evidence of extensive brain white matter lesions. In the hypothesis of an opportunistic brain infection, she underwent brain biopsy of the temporal pole. Pathology results revealed typical NMOSD findings with complement activation, supporting the hypothesis of an atypical presentation of anti-AQP-Ab-associated NMOSD. Accordingly, treatment with the complement-targeting drug eculizumab was started, leading to a dramatic clinical and MRI improvement.</p><p><strong>Discussion: </strong>aseptic meningitis and limbic encephalitis could represent a rare phenotype of anti-AQP4-Ab-associated NMOSD.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1692-1696"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical review: Lactation and use of DMTs in women with MS. 专题回顾:多发性硬化症女性患者的哺乳和 DMTs 的使用。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 Epub Date: 2024-09-30 DOI: 10.1177/13524585241257843
Stephanie Hsu, Ayushi Balan, Riley Bove

One in three females with multiple sclerosis (MS) becomes pregnant after diagnosis. In the postpartum period, there is a risk of rebound inflammatory activity. This risk can likely be reduced with breastfeeding, as well as with early initiation of effective therapies that have low therapeutic lag. To guide patients in their choices surrounding breastfeeding and MS therapies, clinicians must be familiar with how best to protect against relapses, to ensure infant safety, and to support breastfeeding choices. This topical review provides a broad framework on lactation in women with MS. It seeks to reframe guidelines around caring for the maternal-infant dyad, and for diverse populations living with MS. It also provides updated data on the effects of lactation in women with MS and the limited data on transfer of disease-modifying therapies (DMTs) into breastmilk. The ultimate goal is to support informed shared decision-making between clinicians and patients regarding breastfeeding during the high-risk postpartum period.

每三名多发性硬化症(MS)女性患者中就有一人在确诊后怀孕。在产后,炎症活动有反弹的风险。通过母乳喂养以及尽早开始使用治疗滞后期短的有效疗法,可以降低这种风险。为了指导患者选择母乳喂养和多发性硬化症疗法,临床医生必须熟悉如何最好地防止复发、确保婴儿安全并支持母乳喂养的选择。本专题综述为多发性硬化症女性患者的哺乳提供了一个广泛的框架。它旨在重新制定有关照顾母婴二人组和不同多发性硬化症患者的指导原则。它还提供了有关多发性硬化症女性患者哺乳期影响的最新数据,以及有关疾病修饰疗法 (DMT) 转移到母乳中的有限数据。其最终目标是支持临床医生和患者就产后高风险期的母乳喂养做出知情的共同决策。
{"title":"Topical review: Lactation and use of DMTs in women with MS.","authors":"Stephanie Hsu, Ayushi Balan, Riley Bove","doi":"10.1177/13524585241257843","DOIUrl":"10.1177/13524585241257843","url":null,"abstract":"<p><p>One in three females with multiple sclerosis (MS) becomes pregnant after diagnosis. In the postpartum period, there is a risk of rebound inflammatory activity. This risk can likely be reduced with breastfeeding, as well as with early initiation of effective therapies that have low therapeutic lag. To guide patients in their choices surrounding breastfeeding and MS therapies, clinicians must be familiar with how best to protect against relapses, to ensure infant safety, and to support breastfeeding choices. This topical review provides a broad framework on lactation in women with MS. It seeks to reframe guidelines around caring for the maternal-infant dyad, and for diverse populations living with MS. It also provides updated data on the effects of lactation in women with MS and the limited data on transfer of disease-modifying therapies (DMTs) into breastmilk. The ultimate goal is to support informed shared decision-making between clinicians and patients regarding breastfeeding during the high-risk postpartum period.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1578-1591"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
To halt disease progression rehabilitation in MS should start early: Yes. 多发性硬化症的康复治疗应及早开始,以阻止疾病进展:是的。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 DOI: 10.1177/13524585241289268
Jip Aarts, Vincent de Groot
{"title":"To halt disease progression rehabilitation in MS should start early: Yes.","authors":"Jip Aarts, Vincent de Groot","doi":"10.1177/13524585241289268","DOIUrl":"10.1177/13524585241289268","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":"30 13","pages":"1592-1594"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability. 多发性硬化症的淋巴功能障碍及其与疾病病理和残疾的关系。
IF 5.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 Epub Date: 2024-09-29 DOI: 10.1177/13524585241280842
Ahmed Bayoumi, Khader M Hasan, Joseph A Thomas, Akram Yazdani, John A Lincoln

Background: The role of the glymphatic system in multiple sclerosis (MS)-related disability remains underexplored. Diffusion-tensor image analysis along the perivascular space (DTI-ALPS) offers a non-invasive method to assess glymphatic function.

Objective: To evaluate glymphatic function in MS patients with lower and higher disability.

Methods: This study included 118 MS patients who underwent structural, diffusion-weighted imaging, and clinical assessment. The participants were divided into lower (MS-L, n = 57) and higher disability (MS-H, n = 61) subgroups. Brain parenchymal fraction (BPF), lesion load (LL), and DTI-ALPS index were measured. Subgroup differences and correlations between DTI-ALPS index and other measures were explored. Logistic regression was performed to evaluate BPF, LL, and DTI-ALPS index in classifying lower and higher disability patients.

Results: Significant differences in DTI-ALPS index between MS-H and MS-L (d = -0.71, false discovery rate-corrected p-value (p-FDR) = 0.001) were found. The DTI-ALPS index correlated significantly with disease duration (rp = -0.29, p-FDR = 0.002) and EDSS (rsp = -0.35, p-FDR = 0.0002). It also showed significant correlations with BPF and LL. DTI-ALPS index and LL were significant predictors of disability subgroup (DTI-ALPS: odds ratio (OR) = 1.77, p = 0.04, LL: OR = 0.94, p = 0.02).

Conclusion: Our findings highlight DTI-ALPS index as an imaging biomarker in MS, suggesting the involvement of glymphatic impairment in MS pathology, although further research is needed to elucidate its role in contributing to MS-related disability.

背景:甘液系统在多发性硬化症(MS)相关残疾中的作用仍未得到充分探索。沿血管周围空间的弥散张量图像分析(DTI-ALPS)提供了一种非侵入性方法来评估肾脏功能:评估多发性硬化症低度和高度致残患者的肾脏功能:本研究纳入了 118 名接受结构、弥散加权成像和临床评估的多发性硬化症患者。参与者被分为残疾程度较低(MS-L,n = 57)和残疾程度较高(MS-H,n = 61)两组。对脑实质部分(BPF)、病变负荷(LL)和DTI-ALPS指数进行了测量。探讨了亚组差异以及 DTI-ALPS 指数与其他测量指标之间的相关性。对BPF、LL和DTI-ALPS指数进行了逻辑回归,以评估其对残疾程度较低和较高的患者的分级作用:DTI-ALPS指数在MS-H和MS-L之间存在显著差异(d = -0.71,假发现率校正p值(p-FDR) = 0.001)。DTI-ALPS 指数与病程(rp = -0.29,p-FDR = 0.002)和 EDSS(rsp = -0.35,p-FDR = 0.0002)显著相关。它与 BPF 和 LL 也有明显的相关性。DTI-ALPS 指数和 LL 是残疾亚组的重要预测指标(DTI-ALPS:比值比 (OR) = 1.77,P = 0.04;LL:OR = 0.94,P = 0.02):我们的研究结果表明,DTI-ALPS指数是多发性硬化症的一种影像生物标志物,提示多发性硬化症病理中存在肾上腺功能损害,但仍需进一步研究以阐明其在多发性硬化症相关残疾中的作用。
{"title":"Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.","authors":"Ahmed Bayoumi, Khader M Hasan, Joseph A Thomas, Akram Yazdani, John A Lincoln","doi":"10.1177/13524585241280842","DOIUrl":"10.1177/13524585241280842","url":null,"abstract":"<p><strong>Background: </strong>The role of the glymphatic system in multiple sclerosis (MS)-related disability remains underexplored. Diffusion-tensor image analysis along the perivascular space (DTI-ALPS) offers a non-invasive method to assess glymphatic function.</p><p><strong>Objective: </strong>To evaluate glymphatic function in MS patients with lower and higher disability.</p><p><strong>Methods: </strong>This study included 118 MS patients who underwent structural, diffusion-weighted imaging, and clinical assessment. The participants were divided into lower (MS-L, <i>n</i> = 57) and higher disability (MS-H, <i>n</i> = 61) subgroups. Brain parenchymal fraction (BPF), lesion load (LL), and DTI-ALPS index were measured. Subgroup differences and correlations between DTI-ALPS index and other measures were explored. Logistic regression was performed to evaluate BPF, LL, and DTI-ALPS index in classifying lower and higher disability patients.</p><p><strong>Results: </strong>Significant differences in DTI-ALPS index between MS-H and MS-L (<i>d</i> = -0.71, false discovery rate-corrected <i>p</i>-value (<i>p-</i>FDR) = 0.001) were found. The DTI-ALPS index correlated significantly with disease duration (<i>r<sub>p</sub></i> = -0.29, <i>p-</i>FDR = 0.002) and EDSS (<i>r<sub>sp</sub></i> = -0.35, <i>p-</i>FDR = 0.0002). It also showed significant correlations with BPF and LL. DTI-ALPS index and LL were significant predictors of disability subgroup (DTI-ALPS: odds ratio (OR) = 1.77, <i>p</i> = 0.04, LL: OR = 0.94, <i>p</i> = 0.02).</p><p><strong>Conclusion: </strong>Our findings highlight DTI-ALPS index as an imaging biomarker in MS, suggesting the involvement of glymphatic impairment in MS pathology, although further research is needed to elucidate its role in contributing to MS-related disability.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1609-1619"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using serum neurofilament-light in clinical practice: Growing enthusiasm that may need bridling. 在临床实践中使用血清神经纤丝光:日益增长的热情可能需要唤醒。
IF 5.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1177/13524585241291452
Jan Lycke, Robert J Fox
{"title":"Using serum neurofilament-light in clinical practice: Growing enthusiasm that may need bridling.","authors":"Jan Lycke, Robert J Fox","doi":"10.1177/13524585241291452","DOIUrl":"10.1177/13524585241291452","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1575-1577"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JC virus or extended interval dosing? More data are needed. JC病毒还是延长间隔用药?需要更多数据。
IF 5.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-11-01 Epub Date: 2024-09-06 DOI: 10.1177/13524585241272975
Ahmed Z Obeidat
{"title":"JC virus or extended interval dosing? More data are needed.","authors":"Ahmed Z Obeidat","doi":"10.1177/13524585241272975","DOIUrl":"10.1177/13524585241272975","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1698"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Multiple Sclerosis Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1